$CLOV

Reynoso Jamie L. sold $61K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 13,119 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.67 on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Jul 16, 2026, 8:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale of 13,119 shares at $4.6700 on 2026-07-15, filed on 2026-07-16, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider activity, but the 10b5-1 designation and modest transaction value suggest limited incremental trading edge.

03

What to watch

Form 4s often do not capture the full context of insider compensation, tax planning, or concurrent option exercises; the article provides only the sale details.

Relevance 2/10Novelty 3/10Timing: latest Form 4 filed 2026-07-16, covering a sale executed 2026-07-15

Background

The article is a SEC Form 4 insider transaction disclosure for Clover Health Investments Corp. (CLOV).

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health CEO Jamie Reynoso sold 13,119 shares on 2026-07-15 at $4.6700, totaling about $61.3K, under a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, but the article specifies a pre-arranged 10b5-1 plan and the disclosed sale size is modest relative to typical market moves.

Market effects

No clear sector read-through from a single, modest 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

The sale could reflect diversification or liquidity needs rather than bearish expectations, especially given the explicit 10b5-1 plan.

Key entities

  • CLOV

    Clover Health Investments Corp. (issuer of the Form 4).

  • Jamie L. Reynoso

    CEO, Medicare Advantage, who executed the reported open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$CLOVHigh

Clover Health (CLOV) Gets New ‘Buy’ Call, Higher PT, Climbs 8.5%

Clover Health (CLOV) shares rose 8.53% to $4.71 after Deutsche Bank initiated coverage with a 'buy' rating and $6 price target, citing growth potential in Medicare Advantage and its technology platform. The company reported Q2 net income of $28M, up from a $10.6M loss YoY, with revenues increasing 55.6% to $743.2M. Medicare Advantage membership grew 48% to 157,309. Clover raised its net income and revenue guidance for the year. Hedge fund holdings in CLOV increased fourfold to $79.06M.

$CLOVMed

Clover Health (CLOV) Shares Skyrocket, What You Need To Know

Clover Health (CLOV) shares rose 8.5% after Deutsche Bank initiated coverage with a Buy rating and $6.00 price target, citing growth in Medicare Advantage, its Clover Assistant platform, and its risk model. The stock has seen high volatility, with a 24.2% drop last year due to disappointing earnings and lowered guidance. CLOV is up 96.9% YTD but trades 12.3% below its 52-week high.

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

$CLOVHighAI 8/10

Clover Health (CLOV) Turns Profitable As Medicare Membership Explodes

Clover Health (CLOV) reported Q2 2026 net income of $28M, reversing a $10.6M loss from the prior year. Medicare Advantage membership grew 48% YoY to 157,309. Revenue rose 55.6% to $743.2M, and adjusted EBITDA more than doubled. The company raised its full-year guidance, including adjusted EBITDA to $70M-$85M and GAAP net income to $20M-$35M. Cash and investments increased 13.8% YoY to $443.0M.